Charles River Laboratories ROA 2010-2023 | CRL
Current and historical return on assets (ROA) values for Charles River Laboratories (CRL) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Charles River Laboratories ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2023-12-31 | $0.47B | $8.20B | 6.06% |
| 2023-09-30 | $0.47B | $7.61B | 6.18% |
| 2023-06-30 | $0.48B | $7.77B | 6.34% |
| 2023-03-31 | $0.50B | $7.70B | 6.55% |
| 2022-12-31 | $0.49B | $7.60B | 6.56% |
| 2022-09-30 | $0.44B | $7.38B | 6.01% |
| 2022-06-30 | $0.44B | $7.53B | 6.18% |
| 2022-03-31 | $0.42B | $7.08B | 6.06% |
| 2021-12-31 | $0.39B | $7.02B | 5.88% |
| 2021-09-30 | $0.40B | $7.06B | 6.32% |
| 2021-06-30 | $0.40B | $6.72B | 6.82% |
| 2021-03-31 | $0.38B | $5.81B | 6.90% |
| 2020-12-31 | $0.36B | $5.49B | 6.89% |
| 2020-09-30 | $0.30B | $5.21B | 5.92% |
| 2020-06-30 | $0.27B | $5.24B | 5.50% |
| 2020-03-31 | $0.25B | $5.20B | 5.19% |
| 2019-12-31 | $0.25B | $4.69B | 5.65% |
| 2019-09-30 | $0.23B | $4.58B | 5.46% |
| 2019-06-30 | $0.22B | $4.63B | 5.41% |
| 2019-03-31 | $0.23B | $3.93B | 5.93% |
| 2018-12-31 | $0.23B | $3.86B | 6.25% |
| 2018-09-30 | $0.14B | $3.80B | 4.03% |
| 2018-06-30 | $0.13B | $3.87B | 4.07% |
| 2018-03-31 | $0.13B | $3.00B | 4.46% |
| 2017-12-31 | $0.12B | $2.93B | 4.37% |
| 2017-09-30 | $0.20B | $2.87B | 7.17% |
| 2017-06-30 | $0.18B | $2.77B | 6.77% |
| 2017-03-31 | $0.17B | $2.70B | 6.08% |
| 2016-12-31 | $0.16B | $2.71B | 6.04% |
| 2016-09-30 | $0.14B | $2.69B | 5.90% |
| 2016-06-30 | $0.14B | $2.76B | 6.29% |
| 2016-03-31 | $0.16B | $2.10B | 7.66% |
| 2015-12-31 | $0.15B | $2.07B | 7.66% |
| 2015-09-30 | $0.15B | $2.03B | 7.59% |
| 2015-06-30 | $0.14B | $1.89B | 7.52% |
| 2015-03-31 | $0.13B | $1.85B | 6.79% |
| 2014-12-31 | $0.13B | $1.87B | 6.97% |
| 2014-09-30 | $0.12B | $1.84B | 6.75% |
| 2014-06-30 | $0.12B | $1.86B | 6.89% |
| 2014-03-31 | $0.11B | $1.65B | 6.66% |
| 2013-12-31 | $0.10B | $1.63B | 6.34% |
| 2013-09-30 | $0.10B | $1.64B | 6.32% |
| 2013-06-30 | $0.09B | $1.62B | 5.83% |
| 2013-03-31 | $0.10B | $1.60B | 6.09% |
| 2012-12-31 | $0.10B | $1.59B | 6.14% |
| 2012-09-30 | $0.11B | $1.57B | 6.74% |
| 2012-06-30 | $0.10B | $1.55B | 6.53% |
| 2012-03-31 | $0.10B | $1.56B | 6.50% |
| 2011-12-31 | $0.11B | $1.56B | 6.61% |
| 2011-09-30 | $-0.26B | $1.59B | -15.48% |
| 2011-06-30 | $-0.31B | $1.71B | -16.85% |
| 2011-03-31 | $-0.32B | $1.75B | -16.80% |
| 2010-12-31 | $-0.34B | $1.73B | -16.57% |
| 2010-09-30 | $0.02B | $2.08B | 1.11% |
| 2010-06-30 | $0.09B | $2.16B | 3.94% |
| 2010-03-31 | $0.11B | $2.19B | 4.85% |
| 2009-12-31 | $0.11B | $2.20B | 5.28% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.153B | $4.129B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $116.371B | 15.10 |
| Cencora (COR) | United States | $46.721B | 18.65 |
| ICON (ICLR) | Ireland | $24.676B | 24.34 |
| DiDi Global (DIDIY) | China | $22.638B | 0.00 |
| Avantor (AVTR) | United States | $16.760B | 23.09 |
| CochLear (CHEOY) | $13.599B | 0.00 | |
| Viatris (VTRS) | United States | $13.580B | 3.88 |
| Revvity (RVTY) | United States | $12.639B | 22.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $11.999B | 0.00 |
| Medpace Holdings (MEDP) | United States | $11.995B | 43.60 |
| Natera (NTRA) | United States | $10.919B | 0.00 |
| Solventum (SOLV) | $10.642B | 0.00 | |
| Amplifon S.p.A (AMFPF) | Italy | $7.290B | 37.01 |
| HealthEquity (HQY) | United States | $6.884B | 51.43 |
| Bausch + Lomb (BLCO) | Canada | $5.025B | 19.32 |
| Doximity (DOCS) | United States | $4.742B | 35.31 |
| Organon (OGN) | United States | $4.527B | 4.38 |
| Surgery Partners (SGRY) | United States | $3.250B | 30.20 |
| Progyny (PGNY) | United States | $3.249B | 54.53 |
| Sotera Health (SHC) | United States | $3.117B | 15.29 |
| Life Times (LTH) | United States | $2.838B | 31.37 |
| GoodRx Holdings (GDRX) | United States | $2.587B | 131.00 |
| Premier (PINC) | United States | $2.486B | 9.10 |
| Teladoc Health (TDOC) | United States | $2.294B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $2.163B | 7.00 |
| Agilon Health (AGL) | United States | $1.827B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $1.779B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.401B | 0.00 | |
| NovoCure (NVCR) | Jersey | $1.369B | 0.00 |
| Agiliti (AGTI) | United States | $1.365B | 22.31 |
| Alignment Healthcare (ALHC) | United States | $0.890B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.771B | 7.97 |
| Embecta (EMBC) | United States | $0.610B | 4.03 |
| InnovAge Holding (INNV) | United States | $0.563B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.555B | 0.00 |
| Enhabit (EHAB) | United States | $0.523B | 47.41 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.515B | 0.00 |
| MultiPlan (MPLN) | United States | $0.496B | 0.00 |
| Beauty Health (SKIN) | United States | $0.439B | 0.00 |
| CareDx (CDNA) | United States | $0.425B | 0.00 |
| LifeMD (LFMD) | United States | $0.388B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.381B | 0.00 |
| DocGo (DCGO) | United States | $0.339B | 54.17 |
| Sera Prognostics (SERA) | United States | $0.326B | 0.00 |
| ModivCare (MODV) | United States | $0.319B | 4.23 |
| GeneDx Holdings (WGS) | United States | $0.257B | 0.00 |
| Sharecare (SHCR) | United States | $0.256B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.250B | 0.00 |
| Biodesix (BDSX) | United States | $0.121B | 0.00 |
| So-Young (SY) | China | $0.109B | 36.67 |
| Oncology Institute (TOI) | United States | $0.088B | 0.00 |
| Pono Capital Two (PTWO) | United States | $0.063B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.062B | 0.00 |
| NeueHealth (NEUE) | United States | $0.050B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.037B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.037B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.029B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.028B | 0.00 |
| Nutex Health (NUTX) | United States | $0.027B | 0.00 |
| DermTech (DMTK) | United States | $0.021B | 0.00 |
| OncoCyte (OCX) | United States | $0.021B | 0.00 |
| BIMI Medical (BIMI) | United States | $0.015B | 0.00 |
| Aesthetic Medical Hldngs Group (AIH) | China | $0.012B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.011B | 0.00 | |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| TRxADE HEALTH (MEDS) | United States | $0.009B | 0.00 |
| OpGen (OPGN) | United States | $0.007B | 0.00 |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Assure Holdings (IONM) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |